Citi has resumed coverage of Exosens, a supplier of night vision systems to NATO, with a "neutral/high risk" rating, citing potential growth from increased European defense spending. The outlook for defense spending is now extended to 10 years, with expectations of Europe reaching 3% of GDP on defense. Exosens reported a 35% revenue increase and has seen its stock rise nearly 73% year-to-date, with five out of six analysts rating it as "strong buy" or "buy."